妇科癌症患者中PD-L1的患病率和预后角色：一项系统综述和荟萃分析。
Prevalence and Prognostic Role of PD-L1 in Patients with Gynecological Cancers: A Systematic Review and Meta-Analysis.
发表日期：2023 Aug 01
作者：
Hanlin Fu, Zhihui Fu, Meng Mao, Lulu Si, Jing Bai, Qian Wang, Ruixia Guo
来源：
Cell Death & Disease
摘要：
本研究旨在评估程序性细胞死亡配体-1（PD-L1）在宫颈癌（CC）、子宫内膜癌（EC）和卵巢癌（OC）中的表达及其预后意义。我们检索了多个电子数据库。根据情况采用固定效应模型或随机效应模型计算PD-L1阳性的汇总患病率和汇总风险比（HRs）。还评估了异质性和出版偏倚。PD-L1阳性的汇总患病率为CC、EC和OC患者分别为58.1%、33.8%和37.5%。在按照PD-L1阳性评估标准和抗体克隆分层后，汇总估计结果存在显著差异。PD-L1阳性与CC和EC患者的较差总生存期（OS）和CC患者的较差无进展生存期（PFS）相关。CC患者中PD-L1阳性表达的患病率较高，EC和OC患者中表达较为适中。PD-L1表达有潜力成为预测CC和EC患者临床结果的预后标志物，但在OC患者中则不具备预测价值。版权所有 ©2023. Elsevier B.V. 发表。
Our study aims to evaluate programmed cell death ligand-1 (PD-L1) expression and its prognostic significance in cervical cancer (CC), endometrial cancer (EC) and ovarian cancer (OC).Several electronic databases were searched. Fixed effects models or random effects models were employed to calculate the pooled prevalence of PD-L1 positivity and pooled hazard ratios (HRs) as appropriate. Heterogeneity and publication bias were also assessed.The pooled prevalence of PD-L1 positivity was 58.1%, 33.8% and 37.5% for CC, EC and OC patients, respectively. There were significant differences in the pooled estimates after stratification by PD-L1-positive assessment criteria and antibody clones. PD-L1 positivity was associated with worse OS in CC and EC patients and poorer progression-free survival (PFS) in CC patients.The prevalence of PD-L1-positive expression was considerably high in CC and modestly high in EC and OC patients. PD-L1 expression has the potential to be a prognostic biomarker for predicting the clinical outcomes of patients with CC and EC but not OC.Copyright © 2023. Published by Elsevier B.V.